TRIAL DETAIL
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Withdrawn |
|||
Phase: |
2 |
Start Date 11/01/2021 |
Age of Trial (yrs) 3.1 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor + MEK inhibitor |
|||
Strategy: |
Block KIT + Block related tumor signal paths |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
DCC-2618-01-008 |
|||
Sponsor: |
Deciphera Pharmaceuticals LLC |
|||
Patient Contact: |
Study Director
785-830-2100
clinicaltrials@deciphera.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
The Sponsor decided to discontinue this study due to a corporate restructuring intended to prioritize clinical development of select programs. No patients enrolled in this study and no patients received investigational product. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1475 Northwest 12th Ave |
Miami |
FL |
33136 |
USA |
|
1275 York Ave |
New York |
NY |
10065 |
USA |
|
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
610 University Ave |
Toronto |
ON |
M5G 2M9 |
Canada |
|
Hufelandstr. 55 |
Essen |
45122 |
Germany |
||
Barcelona |
08035 |
Spain |